CA2893591A1

CA2893591A1 - Methods for monitoring tight clot formation

Methods for monitoring tight clot formation Download PDF

Info

Publication number: CA2893591A1
Authority: CA; Canada
Prior art keywords: blood sample; sample; clotting; clot; blood
Prior art date: 2012-12-07
Legal status : Abandoned

Application number

CA2893591A

Other languages

English (en)

French (fr)

Inventor

Walter W. Massefski

Thomas Jay Lowery

Lynell R. Skewis

Current Assignee

T2 Biosystems Inc

Original Assignee

T2 Biosystems Inc

Priority date

2012-12-07

Filing date

2013-12-05

Publication date

2014-06-12

2013-12-05 Application filed by T2 Biosystems Inc filed Critical T2 Biosystems Inc

2014-06-12 Publication of CA2893591A1 publication Critical patent/CA2893591A1/en

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 440
230000035602 clotting Effects 0.000 title claims abstract description 260
238000012544 monitoring process Methods 0.000 title claims abstract description 66
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 329
229910001868 water Inorganic materials 0.000 claims abstract description 329
206010053567 Coagulopathies Diseases 0.000 claims abstract description 250
230000008569 process Effects 0.000 claims abstract description 115
230000005291 magnetic effect Effects 0.000 claims abstract description 88
239000008280 blood Substances 0.000 claims description 456
210000004369 blood Anatomy 0.000 claims description 453
238000005259 measurement Methods 0.000 claims description 162
238000004422 calculation algorithm Methods 0.000 claims description 140
102000008946 Fibrinogen Human genes 0.000 claims description 81
108010049003 Fibrinogen Proteins 0.000 claims description 81
229940012952 fibrinogen Drugs 0.000 claims description 80
238000005481 NMR spectroscopy Methods 0.000 claims description 78
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 63
229950003499 fibrin Drugs 0.000 claims description 62
108010073385 Fibrin Proteins 0.000 claims description 61
102000009123 Fibrin Human genes 0.000 claims description 61
239000000463 material Substances 0.000 claims description 60
230000000694 effects Effects 0.000 claims description 59
238000004090 dissolution Methods 0.000 claims description 55
239000003999 initiator Substances 0.000 claims description 49
208000007536 Thrombosis Diseases 0.000 claims description 48
239000012190 activator Substances 0.000 claims description 47
210000002381 plasma Anatomy 0.000 claims description 46
238000005534 hematocrit Methods 0.000 claims description 42
102000002262 Thromboplastin Human genes 0.000 claims description 40
108010000499 Thromboplastin Proteins 0.000 claims description 40
230000008859 change Effects 0.000 claims description 37
230000006870 function Effects 0.000 claims description 37
210000002966 serum Anatomy 0.000 claims description 35
238000002560 therapeutic procedure Methods 0.000 claims description 33
239000003112 inhibitor Substances 0.000 claims description 32
108090000190 Thrombin Proteins 0.000 claims description 31
229960004072 thrombin Drugs 0.000 claims description 31
230000000977 initiatory effect Effects 0.000 claims description 30
208000014674 injury Diseases 0.000 claims description 29
108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 28
102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 28
239000000758 substrate Substances 0.000 claims description 28
229960000187 tissue plasminogen activator Drugs 0.000 claims description 27
238000001228 spectrum Methods 0.000 claims description 26
230000001131 transforming effect Effects 0.000 claims description 24
-1 Abciximab (Reopro) Chemical compound 0.000 claims description 21
239000000203 mixture Substances 0.000 claims description 21
238000004458 analytical method Methods 0.000 claims description 20
208000015294 blood coagulation disease Diseases 0.000 claims description 20
238000001514 detection method Methods 0.000 claims description 20
239000011521 glass Substances 0.000 claims description 19
239000004094 surface-active agent Substances 0.000 claims description 19
210000004623 platelet-rich plasma Anatomy 0.000 claims description 18
108090000623 proteins and genes Proteins 0.000 claims description 18
102000004169 proteins and genes Human genes 0.000 claims description 17
108010035532 Collagen Proteins 0.000 claims description 16
102000008186 Collagen Human genes 0.000 claims description 16
230000015572 biosynthetic process Effects 0.000 claims description 16
229920001436 collagen Polymers 0.000 claims description 16
229940127218 antiplatelet drug Drugs 0.000 claims description 15
238000013176 antiplatelet therapy Methods 0.000 claims description 15
229920005601 base polymer Polymers 0.000 claims description 15
230000003331 prothrombotic effect Effects 0.000 claims description 15
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 14
229930182837 (R)-adrenaline Natural products 0.000 claims description 14
229960005139 epinephrine Drugs 0.000 claims description 14
230000002008 hemorrhagic effect Effects 0.000 claims description 14
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 13
238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 claims description 13
239000000106 platelet aggregation inhibitor Substances 0.000 claims description 13
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
229960000446 abciximab Drugs 0.000 claims description 12
AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims description 11
ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 claims description 11
229920002079 Ellagic acid Polymers 0.000 claims description 11
230000002596 correlated effect Effects 0.000 claims description 11
229960002852 ellagic acid Drugs 0.000 claims description 11
235000004132 ellagic acid Nutrition 0.000 claims description 11
FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 claims description 11
239000003805 procoagulant Substances 0.000 claims description 11
SDZRWUKZFQQKKV-JHADDHBZSA-N cytochalasin D Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@H]\3[C@]2([C@@H](/C=C/[C@@](C)(O)C(=O)[C@@H](C)C/C=C/3)OC(C)=O)C(=O)N1)=C)C)C1=CC=CC=C1 SDZRWUKZFQQKKV-JHADDHBZSA-N 0.000 claims description 10
208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 10
108010039627 Aprotinin Proteins 0.000 claims description 9
229960004405 aprotinin Drugs 0.000 claims description 9
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 9
201000005665 thrombophilia Diseases 0.000 claims description 9
239000004743 Polypropylene Substances 0.000 claims description 8
238000004891 communication Methods 0.000 claims description 8
230000003287 optical effect Effects 0.000 claims description 8
230000036961 partial effect Effects 0.000 claims description 8
239000004417 polycarbonate Substances 0.000 claims description 8
229920000515 polycarbonate Polymers 0.000 claims description 8
229920001155 polypropylene Polymers 0.000 claims description 8
239000004793 Polystyrene Substances 0.000 claims description 7
229920002223 polystyrene Polymers 0.000 claims description 7
229940107685 reopro Drugs 0.000 claims description 6
238000002444 silanisation Methods 0.000 claims description 6
150000001720 carbohydrates Chemical class 0.000 claims description 5
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 5
108091033319 polynucleotide Proteins 0.000 claims description 5
102000040430 polynucleotide Human genes 0.000 claims description 5
239000002157 polynucleotide Substances 0.000 claims description 5
238000009877 rendering Methods 0.000 claims description 5
230000004520 agglutination Effects 0.000 claims description 4
230000001732 thrombotic effect Effects 0.000 claims description 4
230000009466 transformation Effects 0.000 claims description 4
208000010444 Acidosis Diseases 0.000 claims description 3
206010060906 Dilutional coagulopathy Diseases 0.000 claims description 3
206010021113 Hypothermia Diseases 0.000 claims description 3
230000007950 acidosis Effects 0.000 claims description 3
208000026545 acidosis disease Diseases 0.000 claims description 3
238000000835 electrochemical detection Methods 0.000 claims description 3
230000002631 hypothermal effect Effects 0.000 claims description 3
230000001900 immune effect Effects 0.000 claims description 3
230000035939 shock Effects 0.000 claims description 3
101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 claims 2
101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 claims 2
239000000523 sample Substances 0.000 description 501
210000001772 blood platelet Anatomy 0.000 description 176
230000002439 hemostatic effect Effects 0.000 description 60
230000015271 coagulation Effects 0.000 description 52
238000005345 coagulation Methods 0.000 description 52
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 38
230000006399 behavior Effects 0.000 description 37
XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 36
XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 35
239000002245 particle Substances 0.000 description 35
238000001994 activation Methods 0.000 description 34
230000004913 activation Effects 0.000 description 33
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 29
230000020764 fibrinolysis Effects 0.000 description 29
230000023597 hemostasis Effects 0.000 description 29
239000003146 anticoagulant agent Substances 0.000 description 28
238000003556 assay Methods 0.000 description 27
239000000306 component Substances 0.000 description 26
230000007812 deficiency Effects 0.000 description 25
208000009190 disseminated intravascular coagulation Diseases 0.000 description 25
229940127219 anticoagulant drug Drugs 0.000 description 24
229920000669 heparin Polymers 0.000 description 24
238000012360 testing method Methods 0.000 description 24
230000008733 trauma Effects 0.000 description 24
208000032843 Hemorrhage Diseases 0.000 description 23
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
238000004519 manufacturing process Methods 0.000 description 22
206010040047 Sepsis Diseases 0.000 description 21
229940114079 arachidonic acid Drugs 0.000 description 19
235000021342 arachidonic acid Nutrition 0.000 description 19
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 19
239000000654 additive Substances 0.000 description 18
208000034158 bleeding Diseases 0.000 description 18
230000000740 bleeding effect Effects 0.000 description 18
229960002897 heparin Drugs 0.000 description 18
239000005995 Aluminium silicate Substances 0.000 description 17
230000002159 abnormal effect Effects 0.000 description 17
235000012211 aluminium silicate Nutrition 0.000 description 17
210000003743 erythrocyte Anatomy 0.000 description 17
239000003921 oil Substances 0.000 description 17
238000006243 chemical reaction Methods 0.000 description 16
230000037361 pathway Effects 0.000 description 16
239000003795 chemical substances by application Substances 0.000 description 15
238000000576 coating method Methods 0.000 description 15
150000001875 compounds Chemical class 0.000 description 15
239000000126 substance Substances 0.000 description 15
102000015081 Blood Coagulation Factors Human genes 0.000 description 14
108010039209 Blood Coagulation Factors Proteins 0.000 description 14
239000004019 antithrombin Substances 0.000 description 14
239000003114 blood coagulation factor Substances 0.000 description 14
239000000499 gel Substances 0.000 description 14
230000004044 response Effects 0.000 description 14
FHZSIZRTNHGLSX-FLMSMKGQSA-N (2s)-1-[(2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoyl]pyrrolidine-2-carboxyl Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=CC=C1 FHZSIZRTNHGLSX-FLMSMKGQSA-N 0.000 description 13
102000003790 Thrombin receptors Human genes 0.000 description 13
230000010100 anticoagulation Effects 0.000 description 13
230000023555 blood coagulation Effects 0.000 description 13
239000011248 coating agent Substances 0.000 description 13
238000005755 formation reaction Methods 0.000 description 13
230000005764 inhibitory process Effects 0.000 description 13
239000007788 liquid Substances 0.000 description 13
230000007246 mechanism Effects 0.000 description 13
238000012545 processing Methods 0.000 description 13
108010093640 thrombin receptor peptide SFLLRNP Proteins 0.000 description 13
208000030229 desmoplastic infantile ganglioglioma Diseases 0.000 description 12
208000035475 disorder Diseases 0.000 description 12
230000005298 paramagnetic effect Effects 0.000 description 12
239000003153 chemical reaction reagent Substances 0.000 description 11
230000008602 contraction Effects 0.000 description 11
230000003480 fibrinolytic effect Effects 0.000 description 11
230000010118 platelet activation Effects 0.000 description 11
238000001356 surgical procedure Methods 0.000 description 11
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 10
201000010099 disease Diseases 0.000 description 10
238000009826 distribution Methods 0.000 description 10
239000003527 fibrinolytic agent Substances 0.000 description 10
239000000243 solution Substances 0.000 description 10
108010047303 von Willebrand Factor Proteins 0.000 description 10
102000007327 Protamines Human genes 0.000 description 9
108010007568 Protamines Proteins 0.000 description 9
208000027276 Von Willebrand disease Diseases 0.000 description 9
230000001965 increasing effect Effects 0.000 description 9
229920000136 polysorbate Polymers 0.000 description 9
102000005962 receptors Human genes 0.000 description 9
102100036537 von Willebrand factor Human genes 0.000 description 9
229960001134 von willebrand factor Drugs 0.000 description 9
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
101800004937 Protein C Proteins 0.000 description 8
102000017975 Protein C Human genes 0.000 description 8
101800001700 Saposin-D Proteins 0.000 description 8
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 8
230000009089 cytolysis Effects 0.000 description 8
239000003292 glue Substances 0.000 description 8
210000002216 heart Anatomy 0.000 description 8
239000000017 hydrogel Substances 0.000 description 8
239000013610 patient sample Substances 0.000 description 8
229960000856 protein c Drugs 0.000 description 8
108020003175 receptors Proteins 0.000 description 8
230000035945 sensitivity Effects 0.000 description 8
239000002904 solvent Substances 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
238000013169 thromboelastometry Methods 0.000 description 8
208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 8
229910052688 Gadolinium Inorganic materials 0.000 description 7
108010010803 Gelatin Proteins 0.000 description 7
108010094028 Prothrombin Proteins 0.000 description 7
102100027378 Prothrombin Human genes 0.000 description 7
230000001154 acute effect Effects 0.000 description 7
230000000996 additive effect Effects 0.000 description 7
238000013459 approach Methods 0.000 description 7
239000011554 ferrofluid Substances 0.000 description 7
239000012530 fluid Substances 0.000 description 7
UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 7
229920000159 gelatin Polymers 0.000 description 7
235000019322 gelatine Nutrition 0.000 description 7
235000011852 gelatine desserts Nutrition 0.000 description 7
239000003973 paint Substances 0.000 description 7
239000000047 product Substances 0.000 description 7
229940048914 protamine Drugs 0.000 description 7
229920005989 resin Polymers 0.000 description 7
239000011347 resin Substances 0.000 description 7
238000011282 treatment Methods 0.000 description 7
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 6
238000000685 Carr-Purcell-Meiboom-Gill pulse sequence Methods 0.000 description 6
102000004127 Cytokines Human genes 0.000 description 6
108090000695 Cytokines Proteins 0.000 description 6
108010014173 Factor X Proteins 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 6
239000002202 Polyethylene glycol Substances 0.000 description 6
208000006011 Stroke Diseases 0.000 description 6
102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 6
230000005856 abnormality Effects 0.000 description 6
229960001138 acetylsalicylic acid Drugs 0.000 description 6
230000027455 binding Effects 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
230000000875 corresponding effect Effects 0.000 description 6
239000013078 crystal Substances 0.000 description 6
230000006378 damage Effects 0.000 description 6
230000007423 decrease Effects 0.000 description 6
238000003745 diagnosis Methods 0.000 description 6
239000003814 drug Substances 0.000 description 6
238000000605 extraction Methods 0.000 description 6
229940012426 factor x Drugs 0.000 description 6
235000013305 food Nutrition 0.000 description 6
239000008273 gelatin Substances 0.000 description 6
208000015181 infectious disease Diseases 0.000 description 6
SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 6
108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 6
229910044991 metal oxide Inorganic materials 0.000 description 6
150000004706 metal oxides Chemical class 0.000 description 6
229920001223 polyethylene glycol Polymers 0.000 description 6
229940039716 prothrombin Drugs 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
238000012216 screening Methods 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
239000002966 varnish Substances 0.000 description 6
229960005080 warfarin Drugs 0.000 description 6
PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 6
UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 5
FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 5
239000005552 B01AC04 - Clopidogrel Substances 0.000 description 5
108010027612 Batroxobin Proteins 0.000 description 5
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
108010071289 Factor XIII Proteins 0.000 description 5
206010061218 Inflammation Diseases 0.000 description 5
239000001110 calcium chloride Substances 0.000 description 5
229910001628 calcium chloride Inorganic materials 0.000 description 5
235000011148 calcium chloride Nutrition 0.000 description 5
108090001015 cancer procoagulant Proteins 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
229940088598 enzyme Drugs 0.000 description 5
229940012444 factor xiii Drugs 0.000 description 5
238000009472 formulation Methods 0.000 description 5
239000000295 fuel oil Substances 0.000 description 5
230000002757 inflammatory effect Effects 0.000 description 5
230000004054 inflammatory process Effects 0.000 description 5
230000010354 integration Effects 0.000 description 5
238000013167 light transmission aggregometry Methods 0.000 description 5
238000002156 mixing Methods 0.000 description 5
229920000642 polymer Polymers 0.000 description 5
229950008882 polysorbate Drugs 0.000 description 5
230000009467 reduction Effects 0.000 description 5
238000004448 titration Methods 0.000 description 5
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 4
102100022641 Coagulation factor IX Human genes 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
108010054218 Factor VIII Proteins 0.000 description 4
102000001690 Factor VIII Human genes 0.000 description 4
108010088842 Fibrinolysin Proteins 0.000 description 4
208000009292 Hemophilia A Diseases 0.000 description 4
108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 4
102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 4
108010081391 Ristocetin Proteins 0.000 description 4
239000002253 acid Substances 0.000 description 4
230000002411 adverse Effects 0.000 description 4
229960004676 antithrombotic agent Drugs 0.000 description 4
239000010426 asphalt Substances 0.000 description 4
230000008901 benefit Effects 0.000 description 4
238000011088 calibration curve Methods 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
230000000747 cardiac effect Effects 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
229960005188 collagen Drugs 0.000 description 4
230000000052 comparative effect Effects 0.000 description 4
238000009792 diffusion process Methods 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
210000002889 endothelial cell Anatomy 0.000 description 4
230000006624 extrinsic pathway Effects 0.000 description 4
201000007219 factor XI deficiency Diseases 0.000 description 4
229960000301 factor viii Drugs 0.000 description 4
239000000835 fiber Substances 0.000 description 4
208000031169 hemorrhagic disease Diseases 0.000 description 4
230000001771 impaired effect Effects 0.000 description 4
229910052742 iron Inorganic materials 0.000 description 4
239000006249 magnetic particle Substances 0.000 description 4
235000013336 milk Nutrition 0.000 description 4
239000008267 milk Substances 0.000 description 4
210000004080 milk Anatomy 0.000 description 4
238000012806 monitoring device Methods 0.000 description 4
208000010125 myocardial infarction Diseases 0.000 description 4
239000002105 nanoparticle Substances 0.000 description 4
239000002736 nonionic surfactant Substances 0.000 description 4
239000006072 paste Substances 0.000 description 4
150000003904 phospholipids Chemical class 0.000 description 4
230000004962 physiological condition Effects 0.000 description 4
229920003023 plastic Polymers 0.000 description 4
239000004033 plastic Substances 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
229950004257 ristocetin Drugs 0.000 description 4
229960001148 rivaroxaban Drugs 0.000 description 4
KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 description 4
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
239000007787 solid Substances 0.000 description 4
230000003068 static effect Effects 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
206010043554 thrombocytopenia Diseases 0.000 description 4
230000002792 vascular Effects 0.000 description 4
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 3
HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 3
208000002004 Afibrinogenemia Diseases 0.000 description 3
208000024172 Cardiovascular disease Diseases 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
206010051055 Deep vein thrombosis Diseases 0.000 description 3
206010016075 Factor I deficiency Diseases 0.000 description 3
150000000921 Gadolinium Chemical class 0.000 description 3
208000031220 Hemophilia Diseases 0.000 description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
102000013566 Plasminogen Human genes 0.000 description 3
108010051456 Plasminogen Proteins 0.000 description 3
206010073391 Platelet dysfunction Diseases 0.000 description 3
229920001213 Polysorbate 20 Polymers 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229940096437 Protein S Drugs 0.000 description 3
108010066124 Protein S Proteins 0.000 description 3
102000029301 Protein S Human genes 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
WPMWEFXCIYCJSA-UHFFFAOYSA-N Tetraethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCO WPMWEFXCIYCJSA-UHFFFAOYSA-N 0.000 description 3
108010079274 Thrombomodulin Proteins 0.000 description 3
102000012607 Thrombomodulin Human genes 0.000 description 3
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 3
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 3
206010047249 Venous thrombosis Diseases 0.000 description 3
239000000556 agonist Substances 0.000 description 3
150000005215 alkyl ethers Chemical class 0.000 description 3
230000000702 anti-platelet effect Effects 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
239000012503 blood component Substances 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
235000013351 cheese Nutrition 0.000 description 3
BGTFCAQCKWKTRL-YDEUACAXSA-N chembl1095986 Chemical compound C1[C@@H](N)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H]1C(N[C@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(C(=C(O)C=4)C)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@@H](C(=O)N3)[C@H](O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1)=CC=C1OC1=C(O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO[C@@H]5[C@H]([C@@H](O)[C@H](O)[C@@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O3)O)C4=CC2=C1 BGTFCAQCKWKTRL-YDEUACAXSA-N 0.000 description 3
239000004927 clay Substances 0.000 description 3
229960003009 clopidogrel Drugs 0.000 description 3
230000009852 coagulant defect Effects 0.000 description 3
230000001447 compensatory effect Effects 0.000 description 3
239000002131 composite material Substances 0.000 description 3
208000011664 congenital factor XI deficiency Diseases 0.000 description 3
210000004292 cytoskeleton Anatomy 0.000 description 3
229960003850 dabigatran Drugs 0.000 description 3
YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 description 3
DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 3
230000002939 deleterious effect Effects 0.000 description 3
238000000151 deposition Methods 0.000 description 3
230000008021 deposition Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000002592 echocardiography Methods 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
229940049370 fibrinolysis inhibitor Drugs 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
235000019634 flavors Nutrition 0.000 description 3
239000004023 fresh frozen plasma Substances 0.000 description 3
125000000524 functional group Chemical group 0.000 description 3
230000014509 gene expression Effects 0.000 description 3
239000002874 hemostatic agent Substances 0.000 description 3
230000002440 hepatic effect Effects 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
239000001257 hydrogen Substances 0.000 description 3
230000006698 induction Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
230000006623 intrinsic pathway Effects 0.000 description 3
230000000302 ischemic effect Effects 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
230000036210 malignancy Effects 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
239000000123 paper Substances 0.000 description 3
229940012957 plasmin Drugs 0.000 description 3
238000012123 point-of-care testing Methods 0.000 description 3
238000006116 polymerization reaction Methods 0.000 description 3
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
238000001472 pulsed field gradient Methods 0.000 description 3
230000009257 reactivity Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
230000004043 responsiveness Effects 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
235000015067 sauces Nutrition 0.000 description 3
238000000926 separation method Methods 0.000 description 3
208000007056 sickle cell anemia Diseases 0.000 description 3
230000035882 stress Effects 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
239000003868 thrombin inhibitor Substances 0.000 description 3
230000002861 ventricular Effects 0.000 description 3
NMSBTWLFBGNKON-UHFFFAOYSA-N 2-(2-hexadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCO NMSBTWLFBGNKON-UHFFFAOYSA-N 0.000 description 2
ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 description 2
HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
KWVPFECTOKLOBL-KTKRTIGZSA-N 2-[(z)-octadec-9-enoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCO KWVPFECTOKLOBL-KTKRTIGZSA-N 0.000 description 2
MGYUQZIGNZFZJS-KTKRTIGZSA-N 2-[2-[(z)-octadec-9-enoxy]ethoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCO MGYUQZIGNZFZJS-KTKRTIGZSA-N 0.000 description 2
NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 2
JKXYOQDLERSFPT-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO JKXYOQDLERSFPT-UHFFFAOYSA-N 0.000 description 2
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
208000009206 Abruptio Placentae Diseases 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
208000005952 Amniotic Fluid Embolism Diseases 0.000 description 2
206010067010 Anaphylactoid syndrome of pregnancy Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
206010003658 Atrial Fibrillation Diseases 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
239000005465 B01AC22 - Prasugrel Substances 0.000 description 2
QYOVMAREBTZLBT-KTKRTIGZSA-N CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO QYOVMAREBTZLBT-KTKRTIGZSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
102100023804 Coagulation factor VII Human genes 0.000 description 2
102100026735 Coagulation factor VIII Human genes 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
229940123900 Direct thrombin inhibitor Drugs 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
208000017701 Endocrine disease Diseases 0.000 description 2
206010016076 Factor II deficiency Diseases 0.000 description 2
108010076282 Factor IX Proteins 0.000 description 2
108010023321 Factor VII Proteins 0.000 description 2
201000003542 Factor VIII deficiency Diseases 0.000 description 2
108010074864 Factor XI Proteins 0.000 description 2
201000007176 Factor XII Deficiency Diseases 0.000 description 2
108010074860 Factor Xa Proteins 0.000 description 2
239000004812 Fluorinated ethylene propylene Substances 0.000 description 2
206010017533 Fungal infection Diseases 0.000 description 2
206010018910 Haemolysis Diseases 0.000 description 2
108010054147 Hemoglobins Proteins 0.000 description 2
102000001554 Hemoglobins Human genes 0.000 description 2
201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 2
206010019617 Henoch-Schonlein purpura Diseases 0.000 description 2
108010022901 Heparin Lyase Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
206010051125 Hypofibrinogenaemia Diseases 0.000 description 2
208000007646 Hypoprothrombinemias Diseases 0.000 description 2
208000031814 IgA Vasculitis Diseases 0.000 description 2
102000000589 Interleukin-1 Human genes 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
229920002884 Laureth 4 Polymers 0.000 description 2
208000002720 Malnutrition Diseases 0.000 description 2
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
208000031888 Mycoses Diseases 0.000 description 2
208000008589 Obesity Diseases 0.000 description 2
206010053159 Organ failure Diseases 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
208000030852 Parasitic disease Diseases 0.000 description 2
229920001944 Plastisol Polymers 0.000 description 2
108010003541 Platelet Activating Factor Proteins 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
229920001214 Polysorbate 60 Polymers 0.000 description 2
239000004372 Polyvinyl alcohol Substances 0.000 description 2
206010040070 Septic Shock Diseases 0.000 description 2
102000012479 Serine Proteases Human genes 0.000 description 2
108010022999 Serine Proteases Proteins 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
108010023197 Streptokinase Proteins 0.000 description 2
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
208000003441 Transfusion reaction Diseases 0.000 description 2
206010052779 Transplant rejections Diseases 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000009471 action Effects 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
230000002785 anti-thrombosis Effects 0.000 description 2
239000000504 antifibrinolytic agent Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
238000013528 artificial neural network Methods 0.000 description 2
238000000889 atomisation Methods 0.000 description 2
239000002585 base Substances 0.000 description 2
239000012472 biological sample Substances 0.000 description 2
229920001400 block copolymer Polymers 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
238000007675 cardiac surgery Methods 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
238000004140 cleaning Methods 0.000 description 2
239000003250 coal slurry Substances 0.000 description 2
239000010941 cobalt Substances 0.000 description 2
229910017052 cobalt Inorganic materials 0.000 description 2
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
201000007182 congenital afibrinogenemia Diseases 0.000 description 2
238000011109 contamination Methods 0.000 description 2
208000029078 coronary artery disease Diseases 0.000 description 2
239000002537 cosmetic Substances 0.000 description 2
239000010779 crude oil Substances 0.000 description 2
230000007547 defect Effects 0.000 description 2
239000003599 detergent Substances 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
238000007876 drug discovery Methods 0.000 description 2
230000004064 dysfunction Effects 0.000 description 2
235000013399 edible fruits Nutrition 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
210000003038 endothelium Anatomy 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
229960000610 enoxaparin Drugs 0.000 description 2
239000003822 epoxy resin Substances 0.000 description 2
SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 2
201000007382 factor V deficiency Diseases 0.000 description 2
208000005376 factor X deficiency Diseases 0.000 description 2
229960004222 factor ix Drugs 0.000 description 2
229940012413 factor vii Drugs 0.000 description 2
238000000855 fermentation Methods 0.000 description 2
230000004151 fermentation Effects 0.000 description 2
230000005294 ferromagnetic effect Effects 0.000 description 2
235000013373 food additive Nutrition 0.000 description 2
239000002778 food additive Substances 0.000 description 2
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
229910052737 gold Inorganic materials 0.000 description 2
239000010931 gold Substances 0.000 description 2
210000003709 heart valve Anatomy 0.000 description 2
208000009429 hemophilia B Diseases 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
231100000283 hepatitis Toxicity 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
208000015446 immunoglobulin a vasculitis Diseases 0.000 description 2
239000007943 implant Substances 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
208000017169 kidney disease Diseases 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
229910052748 manganese Inorganic materials 0.000 description 2
239000011572 manganese Substances 0.000 description 2
239000003264 margarine Substances 0.000 description 2
235000013310 margarine Nutrition 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
230000035772 mutation Effects 0.000 description 2
235000020824 obesity Nutrition 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
208000024691 pancreas disease Diseases 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
229920009441 perflouroethylene propylene Polymers 0.000 description 2
239000003209 petroleum derivative Substances 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
201000008532 placental abruption Diseases 0.000 description 2
239000004999 plastisol Substances 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
229940020573 plavix Drugs 0.000 description 2
ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 2
229920001983 poloxamer Polymers 0.000 description 2
229920000052 poly(p-xylylene) Polymers 0.000 description 2
239000004584 polyacrylic acid Substances 0.000 description 2
229920006122 polyamide resin Polymers 0.000 description 2
229920000647 polyepoxide Polymers 0.000 description 2
239000002952 polymeric resin Substances 0.000 description 2
229920001296 polysiloxane Polymers 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
229920001343 polytetrafluoroethylene Polymers 0.000 description 2
229920002451 polyvinyl alcohol Polymers 0.000 description 2
235000019422 polyvinyl alcohol Nutrition 0.000 description 2
229920000915 polyvinyl chloride Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 description 2
229960004197 prasugrel Drugs 0.000 description 2
230000035935 pregnancy Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000000770 proinflammatory effect Effects 0.000 description 2
229950008679 protamine sulfate Drugs 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
238000010791 quenching Methods 0.000 description 2
230000005855 radiation Effects 0.000 description 2
238000000518 rheometry Methods 0.000 description 2
238000005070 sampling Methods 0.000 description 2
230000036303 septic shock Effects 0.000 description 2
229940076279 serotonin Drugs 0.000 description 2
230000000391 smoking effect Effects 0.000 description 2
229940035044 sorbitan monolaurate Drugs 0.000 description 2
229960005202 streptokinase Drugs 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
229920003002 synthetic resin Polymers 0.000 description 2
239000010409 thin film Substances 0.000 description 2
229960000103 thrombolytic agent Drugs 0.000 description 2
230000003558 thrombophilic effect Effects 0.000 description 2
DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 2
229960003425 tirofiban Drugs 0.000 description 2
COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 2
238000000844 transformation Methods 0.000 description 2
230000007704 transition Effects 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
229960005356 urokinase Drugs 0.000 description 2
235000013618 yogurt Nutrition 0.000 description 2
GRYSXUXXBDSYRT-WOUKDFQISA-N (2r,3r,4r,5r)-2-(hydroxymethyl)-4-methoxy-5-[6-(methylamino)purin-9-yl]oxolan-3-ol Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1OC GRYSXUXXBDSYRT-WOUKDFQISA-N 0.000 description 1
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
HAGOWCONESKMDW-FRSCJGFNSA-N (2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CC=CC=C1 HAGOWCONESKMDW-FRSCJGFNSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
ORLFVWPPBMVPNZ-UHFFFAOYSA-N 1-(6-methylheptyl)-4-[4-(6-methylheptyl)phenoxy]benzene Chemical class C1=CC(CCCCCC(C)C)=CC=C1OC1=CC=C(CCCCCC(C)C)C=C1 ORLFVWPPBMVPNZ-UHFFFAOYSA-N 0.000 description 1
CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
KGULFLCOPRYBEV-KTKRTIGZSA-N 2-[2-[2-[(z)-octadec-9-enoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCO KGULFLCOPRYBEV-KTKRTIGZSA-N 0.000 description 1
HNUQMTZUNUBOLQ-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO HNUQMTZUNUBOLQ-UHFFFAOYSA-N 0.000 description 1
WMPGRAUYWYBJKX-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO WMPGRAUYWYBJKX-UHFFFAOYSA-N 0.000 description 1
IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
RMWVZGDJPAKBDE-UHFFFAOYSA-N 2-acetyloxy-4-(trifluoromethyl)benzoic acid Chemical compound CC(=O)OC1=CC(C(F)(F)F)=CC=C1C(O)=O RMWVZGDJPAKBDE-UHFFFAOYSA-N 0.000 description 1
ZBMRKNMTMPPMMK-UHFFFAOYSA-N 2-amino-4-[hydroxy(methyl)phosphoryl]butanoic acid;azane Chemical compound [NH4+].CP(O)(=O)CCC(N)C([O-])=O ZBMRKNMTMPPMMK-UHFFFAOYSA-N 0.000 description 1
CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
KXGFMDJXCMQABM-UHFFFAOYSA-N 2-methoxy-6-methylphenol Chemical compound [CH]OC1=CC=CC([CH])=C1O KXGFMDJXCMQABM-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
BPPVUXSMLBXYGG-UHFFFAOYSA-N 4-[3-(4,5-dihydro-1,2-oxazol-3-yl)-2-methyl-4-methylsulfonylbenzoyl]-2-methyl-1h-pyrazol-3-one Chemical compound CC1=C(C(=O)C=2C(N(C)NC=2)=O)C=CC(S(C)(=O)=O)=C1C1=NOCC1 BPPVUXSMLBXYGG-UHFFFAOYSA-N 0.000 description 1
KYWCWBXGRWWINE-UHFFFAOYSA-N 4-methoxy-N1,N3-bis(3-pyridinylmethyl)benzene-1,3-dicarboxamide Chemical compound COC1=CC=C(C(=O)NCC=2C=NC=CC=2)C=C1C(=O)NCC1=CC=CN=C1 KYWCWBXGRWWINE-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
108010043137 Actomyosin Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
208000011403 Alexander disease Diseases 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
108010001779 Ancrod Proteins 0.000 description 1
206010002329 Aneurysm Diseases 0.000 description 1
206010002388 Angina unstable Diseases 0.000 description 1
235000019737 Animal fat Nutrition 0.000 description 1
108010058207 Anistreplase Proteins 0.000 description 1
208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
108090000935 Antithrombin III Proteins 0.000 description 1
102000004411 Antithrombin III Human genes 0.000 description 1
206010003178 Arterial thrombosis Diseases 0.000 description 1
239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
208000031729 Bacteremia Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241001474374 Blennius Species 0.000 description 1
108010073975 Brinolase Proteins 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
235000008733 Citrus aurantifolia Nutrition 0.000 description 1
241001091551 Clio Species 0.000 description 1
206010067787 Coagulation factor deficiency Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000002330 Congenital Heart Defects Diseases 0.000 description 1
208000033131 Congenital factor II deficiency Diseases 0.000 description 1
208000011029 Congenital factor XII deficiency Diseases 0.000 description 1
208000034656 Contusions Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
108010037464 Cyclooxygenase 1 Proteins 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
208000005156 Dehydration Diseases 0.000 description 1
229920000045 Dermatan sulfate Polymers 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
JYGLAHSAISAEAL-UHFFFAOYSA-N Diphenadione Chemical compound O=C1C2=CC=CC=C2C(=O)C1C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 JYGLAHSAISAEAL-UHFFFAOYSA-N 0.000 description 1
238000004435 EPR spectroscopy Methods 0.000 description 1
206010014080 Ecchymosis Diseases 0.000 description 1
108010014258 Elastin Proteins 0.000 description 1
102000016942 Elastin Human genes 0.000 description 1
108010056764 Eptifibatide Proteins 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
229910052693 Europium Inorganic materials 0.000 description 1
108010014172 Factor V Proteins 0.000 description 1
108010054265 Factor VIIa Proteins 0.000 description 1
108010080865 Factor XII Proteins 0.000 description 1
102000000429 Factor XII Human genes 0.000 description 1
201000007371 Factor XIII Deficiency Diseases 0.000 description 1
108010058861 Fibrin Fibrinogen Degradation Products Proteins 0.000 description 1
206010016803 Fluid overload Diseases 0.000 description 1
206010055690 Foetal death Diseases 0.000 description 1
206010016880 Folate deficiency Diseases 0.000 description 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical group O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
208000023329 Gun shot wound Diseases 0.000 description 1
238000008481 HEMOCHRON Response Methods 0.000 description 1
208000008899 Habitual abortion Diseases 0.000 description 1
206010058423 Haemangioma-thrombocytopenia syndrome Diseases 0.000 description 1
206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
206010019663 Hepatic failure Diseases 0.000 description 1
208000028782 Hereditary disease Diseases 0.000 description 1
108010007267 Hirudins Proteins 0.000 description 1
102000007625 Hirudins Human genes 0.000 description 1
101000651439 Homo sapiens Prothrombin Proteins 0.000 description 1
101000635804 Homo sapiens Tissue factor Proteins 0.000 description 1
101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
206010020608 Hypercoagulation Diseases 0.000 description 1
208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
208000028622 Immune thrombocytopenia Diseases 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
206010022971 Iron Deficiencies Diseases 0.000 description 1
208000032382 Ischaemic stroke Diseases 0.000 description 1
208000010299 Kasabach-Merritt syndrome Diseases 0.000 description 1
240000008415 Lactuca sativa Species 0.000 description 1
102000007547 Laminin Human genes 0.000 description 1
108010085895 Laminin Proteins 0.000 description 1
206010067125 Liver injury Diseases 0.000 description 1
235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229920000877 Melamine resin Polymers 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
206010061298 Mucosal haemorrhage Diseases 0.000 description 1
208000034486 Multi-organ failure Diseases 0.000 description 1
108010074084 Muscle Proteins Proteins 0.000 description 1
102000008934 Muscle Proteins Human genes 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
108060008487 Myosin Proteins 0.000 description 1
102000003505 Myosin Human genes 0.000 description 1
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
244000061176 Nicotiana tabacum Species 0.000 description 1
235000002637 Nicotiana tabacum Nutrition 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
208000016222 Pancreatic disease Diseases 0.000 description 1
108010067372 Pancreatic elastase Proteins 0.000 description 1
102000016387 Pancreatic elastase Human genes 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
208000009344 Penetrating Wounds Diseases 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
229920001774 Perfluoroether Polymers 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 1
108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 1
208000013544 Platelet disease Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
208000008601 Polycythemia Diseases 0.000 description 1
229920002367 Polyisobutene Polymers 0.000 description 1
239000004721 Polyphenylene oxide Substances 0.000 description 1
229920001219 Polysorbate 40 Polymers 0.000 description 1
206010036608 Premature separation of placenta Diseases 0.000 description 1
102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
239000004365 Protease Substances 0.000 description 1
201000005660 Protein C Deficiency Diseases 0.000 description 1
206010051292 Protein S Deficiency Diseases 0.000 description 1
208000010378 Pulmonary Embolism Diseases 0.000 description 1
108091030071 RNAI Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
101000611641 Rattus norvegicus Protein phosphatase 1 regulatory subunit 15A Proteins 0.000 description 1
101710148748 Response regulator GacA Proteins 0.000 description 1
241000606651 Rickettsiales Species 0.000 description 1
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
239000002262 Schiff base Substances 0.000 description 1
150000004753 Schiff bases Chemical class 0.000 description 1
102000008847 Serpin Human genes 0.000 description 1
108050000761 Serpin Proteins 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
240000003768 Solanum lycopersicum Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229920000439 Sulodexide Polymers 0.000 description 1
206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
IDCBOTIENDVCBQ-UHFFFAOYSA-N TEPP Chemical compound CCOP(=O)(OCC)OP(=O)(OCC)OCC IDCBOTIENDVCBQ-UHFFFAOYSA-N 0.000 description 1
108010039185 Tenecteplase Proteins 0.000 description 1
WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
229940122388 Thrombin inhibitor Drugs 0.000 description 1
208000005485 Thrombocytosis Diseases 0.000 description 1
102000002938 Thrombospondin Human genes 0.000 description 1
108060008245 Thrombospondin Proteins 0.000 description 1
235000011941 Tilia x europaea Nutrition 0.000 description 1
108060008539 Transglutaminase Proteins 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010064534 Umbilical cord haemorrhage Diseases 0.000 description 1
208000007814 Unstable Angina Diseases 0.000 description 1
102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
206010058990 Venous occlusion Diseases 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
229930003779 Vitamin B12 Natural products 0.000 description 1
108010031318 Vitronectin Proteins 0.000 description 1
102100035140 Vitronectin Human genes 0.000 description 1
229910052769 Ytterbium Inorganic materials 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
229960002054 acenocoumarol Drugs 0.000 description 1
VABCILAOYCMVPS-UHFFFAOYSA-N acenocoumarol Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=C([N+]([O-])=O)C=C1 VABCILAOYCMVPS-UHFFFAOYSA-N 0.000 description 1
208000016804 acquired coagulation factor deficiency Diseases 0.000 description 1
208000017733 acquired polycythemia vera Diseases 0.000 description 1
201000004208 acquired thrombocytopenia Diseases 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000002998 adhesive polymer Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000004931 aggregating effect Effects 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
229910045601 alloy Inorganic materials 0.000 description 1
239000000956 alloy Substances 0.000 description 1
229960004685 aloxiprin Drugs 0.000 description 1
MANKSFVECICGLK-UHFFFAOYSA-K aloxiprin Chemical compound [OH-].[Al+3].CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O MANKSFVECICGLK-UHFFFAOYSA-K 0.000 description 1
229960003318 alteplase Drugs 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
229960004233 ancrod Drugs 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
229960000983 anistreplase Drugs 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000002429 anti-coagulating effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000006502 antiplatelets effects Effects 0.000 description 1
229960005348 antithrombin iii Drugs 0.000 description 1
208000007474 aortic aneurysm Diseases 0.000 description 1
229960003856 argatroban Drugs 0.000 description 1
KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
208000021328 arterial occlusion Diseases 0.000 description 1
238000002820 assay format Methods 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
235000008452 baby food Nutrition 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
235000013405 beer Nutrition 0.000 description 1
229960003616 bemiparin Drugs 0.000 description 1
229960002890 beraprost Drugs 0.000 description 1
CTPOHARTNNSRSR-APJZLKAGSA-N beraprost Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC(O)=O CTPOHARTNNSRSR-APJZLKAGSA-N 0.000 description 1
235000013361 beverage Nutrition 0.000 description 1
230000009141 biological interaction Effects 0.000 description 1
108010055460 bivalirudin Proteins 0.000 description 1
OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
229960001500 bivalirudin Drugs 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000010836 blood and blood product Substances 0.000 description 1
229940125691 blood product Drugs 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
235000008429 bread Nutrition 0.000 description 1
229960002473 brinase Drugs 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
229960005069 calcium Drugs 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229960004105 carbasalate calcium Drugs 0.000 description 1
VYMUGTALCSPLDM-UHFFFAOYSA-L carbasalate calcium Chemical compound [Ca+2].NC(N)=O.CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O VYMUGTALCSPLDM-UHFFFAOYSA-L 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
150000007942 carboxylates Chemical group 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000002612 cardiopulmonary effect Effects 0.000 description 1
230000007211 cardiovascular event Effects 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
235000019219 chocolate Nutrition 0.000 description 1
230000004087 circulation Effects 0.000 description 1
208000035850 clinical syndrome Diseases 0.000 description 1
229960002571 cloricromen Drugs 0.000 description 1
GYNNRVJJLAVVTQ-UHFFFAOYSA-N cloricromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=C(Cl)C(OCC(=O)OCC)=CC=C21 GYNNRVJJLAVVTQ-UHFFFAOYSA-N 0.000 description 1
229960001307 clorindione Drugs 0.000 description 1
NJDUWAXIURWWLN-UHFFFAOYSA-N clorindione Chemical compound C1=CC(Cl)=CC=C1C1C(=O)C2=CC=CC=C2C1=O NJDUWAXIURWWLN-UHFFFAOYSA-N 0.000 description 1
239000000701 coagulant Substances 0.000 description 1
239000010883 coal ash Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
208000028831 congenital heart disease Diseases 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000003851 corona treatment Methods 0.000 description 1
238000007887 coronary angioplasty Methods 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
238000005336 cracking Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
239000010730 cutting oil Substances 0.000 description 1
210000004395 cytoplasmic granule Anatomy 0.000 description 1
229960004969 dalteparin Drugs 0.000 description 1
229960003828 danaparoid Drugs 0.000 description 1
238000013480 data collection Methods 0.000 description 1
238000013075 data extraction Methods 0.000 description 1
230000034994 death Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
229960004120 defibrotide Drugs 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
210000003298 dental enamel Anatomy 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
229940051593 dermatan sulfate Drugs 0.000 description 1
238000013461 design Methods 0.000 description 1
XYWBJDRHGNULKG-OUMQNGNKSA-N desirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 XYWBJDRHGNULKG-OUMQNGNKSA-N 0.000 description 1
108010073652 desirudin Proteins 0.000 description 1
229960000296 desirudin Drugs 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
150000004985 diamines Chemical class 0.000 description 1
229960001912 dicoumarol Drugs 0.000 description 1
DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 description 1
HIZKPJUTKKJDGA-UHFFFAOYSA-N dicumarol Natural products O=C1OC2=CC=CC=C2C(=O)C1CC1C(=O)C2=CC=CC=C2OC1=O HIZKPJUTKKJDGA-UHFFFAOYSA-N 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000003748 differential diagnosis Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000002597 diffusion-weighted imaging Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229960000267 diphenadione Drugs 0.000 description 1
229960002768 dipyridamole Drugs 0.000 description 1
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
229940019332 direct factor xa inhibitors Drugs 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000004821 distillation Methods 0.000 description 1
229960005067 ditazole Drugs 0.000 description 1
UUCMDZWCRNZCOY-UHFFFAOYSA-N ditazole Chemical compound O1C(N(CCO)CCO)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 UUCMDZWCRNZCOY-UHFFFAOYSA-N 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000005553 drilling Methods 0.000 description 1
229940056176 drotrecogin alfa Drugs 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
230000008482 dysregulation Effects 0.000 description 1
208000002296 eclampsia Diseases 0.000 description 1
229920002549 elastin Polymers 0.000 description 1
206010014665 endocarditis Diseases 0.000 description 1
208000030172 endocrine system disease Diseases 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
229960001123 epoprostenol Drugs 0.000 description 1
KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
229960004468 eptifibatide Drugs 0.000 description 1
CZKPOZZJODAYPZ-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CNC2=CC=CC=C12 CZKPOZZJODAYPZ-LROMGURASA-N 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
229960002822 ethyl biscoumacetate Drugs 0.000 description 1
SEGSDVUVOWIWFX-UHFFFAOYSA-N ethyl biscoumacetate Chemical compound C1=CC=C2C(=O)C(C(C=3C(C4=CC=CC=C4OC=3O)=O)C(=O)OCC)=C(O)OC2=C1 SEGSDVUVOWIWFX-UHFFFAOYSA-N 0.000 description 1
OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
235000020187 evaporated milk Nutrition 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000002979 fabric softener Substances 0.000 description 1
201000007386 factor VII deficiency Diseases 0.000 description 1
238000000556 factor analysis Methods 0.000 description 1
208000027826 familial dysfibrinogenemia Diseases 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000009123 feedback regulation Effects 0.000 description 1
230000005293 ferrimagnetic effect Effects 0.000 description 1
239000000208 fibrin degradation product Substances 0.000 description 1
229940001501 fibrinolysin Drugs 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000002124 flame ionisation detection Methods 0.000 description 1
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 description 1
229960001318 fondaparinux Drugs 0.000 description 1
235000003132 food thickener Nutrition 0.000 description 1
229960004279 formaldehyde Drugs 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
235000015203 fruit juice Nutrition 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
239000000446 fuel Substances 0.000 description 1
238000011990 functional testing Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
230000009368 gene silencing by RNA Effects 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
150000003278 haem Chemical class 0.000 description 1
XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
208000011316 hemodynamic instability Diseases 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
229940019334 heparin group antithrombotic drug Drugs 0.000 description 1
231100000234 hepatic damage Toxicity 0.000 description 1
208000013746 hereditary thrombophilia due to congenital protein C deficiency Diseases 0.000 description 1
SYECJBOWSGTPLU-UHFFFAOYSA-N hexane-1,1-diamine Chemical compound CCCCCC(N)N SYECJBOWSGTPLU-UHFFFAOYSA-N 0.000 description 1
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
229940006607 hirudin Drugs 0.000 description 1
239000012943 hotmelt Substances 0.000 description 1
239000010720 hydraulic oil Substances 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000003027 hypercoagulation Effects 0.000 description 1
230000003225 hyperhomocysteinemia Effects 0.000 description 1
208000020346 hyperlipoproteinemia Diseases 0.000 description 1
208000006575 hypertriglyceridemia Diseases 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
235000015243 ice cream Nutrition 0.000 description 1
229960002240 iloprost Drugs 0.000 description 1
HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 description 1
238000002847 impedance measurement Methods 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
229960003422 indobufen Drugs 0.000 description 1
AYDXAULLCROVIT-UHFFFAOYSA-N indobufen Chemical compound C1=CC(C(C(O)=O)CC)=CC=C1N1C(=O)C2=CC=CC=C2C1 AYDXAULLCROVIT-UHFFFAOYSA-N 0.000 description 1
239000000411 inducer Substances 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
201000004332 intermediate coronary syndrome Diseases 0.000 description 1
229910000765 intermetallic Inorganic materials 0.000 description 1
238000012977 invasive surgical procedure Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
159000000014 iron salts Chemical class 0.000 description 1
WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
MVZXTUSAYBWAAM-UHFFFAOYSA-N iron;sulfuric acid Chemical compound [Fe].OS(O)(=O)=O MVZXTUSAYBWAAM-UHFFFAOYSA-N 0.000 description 1
KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
238000002955 isolation Methods 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
239000011499 joint compound Substances 0.000 description 1
238000011813 knockout mouse model Methods 0.000 description 1
238000009533 lab test Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
229910021644 lanthanide ion Inorganic materials 0.000 description 1
229910052746 lanthanum Inorganic materials 0.000 description 1
FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
229940100556 laureth-23 Drugs 0.000 description 1
229940061515 laureth-4 Drugs 0.000 description 1
229940062711 laureth-9 Drugs 0.000 description 1
150000002611 lead compounds Chemical class 0.000 description 1
OTQCKZUSUGYWBD-BRHMIFOHSA-N lepirudin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 OTQCKZUSUGYWBD-BRHMIFOHSA-N 0.000 description 1
229960004408 lepirudin Drugs 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000004571 lime Substances 0.000 description 1
230000008818 liver damage Effects 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
208000007903 liver failure Diseases 0.000 description 1
231100000835 liver failure Toxicity 0.000 description 1
230000003908 liver function Effects 0.000 description 1
244000144972 livestock Species 0.000 description 1
229940118179 lovenox Drugs 0.000 description 1
238000010997 low field NMR spectroscopy Methods 0.000 description 1
239000003055 low molecular weight heparin Substances 0.000 description 1
229940127215 low-molecular weight heparin Drugs 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000000696 magnetic material Substances 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
238000007885 magnetic separation Methods 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
235000000824 malnutrition Nutrition 0.000 description 1
230000001071 malnutrition Effects 0.000 description 1
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
238000012067 mathematical method Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000008268 mayonnaise Substances 0.000 description 1
235000010746 mayonnaise Nutrition 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 description 1
229960002137 melagatran Drugs 0.000 description 1
JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
230000009245 menopause Effects 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
230000004089 microcirculation Effects 0.000 description 1
238000002094 microwave spectroscopy Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
230000002071 myeloproliferative effect Effects 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
229960000899 nadroparin Drugs 0.000 description 1
239000002086 nanomaterial Substances 0.000 description 1
230000014508 negative regulation of coagulation Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
150000002816 nickel compounds Chemical class 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
229910000510 noble metal Inorganic materials 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000010606 normalization Methods 0.000 description 1
235000018343 nutrient deficiency Nutrition 0.000 description 1
208000015380 nutritional deficiency disease Diseases 0.000 description 1
230000000050 nutritive effect Effects 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
229920002114 octoxynol-9 Polymers 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
229940099570 oleth-2 Drugs 0.000 description 1
229940095127 oleth-20 Drugs 0.000 description 1
229940075643 oleth-3 Drugs 0.000 description 1
229940093446 oleth-5 Drugs 0.000 description 1
230000009210 ongoing activation Effects 0.000 description 1
238000005457 optimization Methods 0.000 description 1
229940127234 oral contraceptive Drugs 0.000 description 1
239000003539 oral contraceptive agent Substances 0.000 description 1
230000008816 organ damage Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
230000005414 paramagnetic center Effects 0.000 description 1
229960004762 parnaparin Drugs 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
208000030613 peripheral artery disease Diseases 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229960000280 phenindione Drugs 0.000 description 1
NFBAXHOPROOJAW-UHFFFAOYSA-N phenindione Chemical compound O=C1C2=CC=CC=C2C(=O)C1C1=CC=CC=C1 NFBAXHOPROOJAW-UHFFFAOYSA-N 0.000 description 1
229920001568 phenolic resin Polymers 0.000 description 1
239000005011 phenolic resin Substances 0.000 description 1
229960004923 phenprocoumon Drugs 0.000 description 1
DQDAYGNAKTZFIW-UHFFFAOYSA-N phenprocoumon Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC)C1=CC=CC=C1 DQDAYGNAKTZFIW-UHFFFAOYSA-N 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
229960001006 picotamide Drugs 0.000 description 1
238000009829 pitch coating Methods 0.000 description 1
238000001020 plasma etching Methods 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
239000011505 plaster Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
208000037244 polycythemia vera Diseases 0.000 description 1
229920001225 polyester resin Polymers 0.000 description 1
239000004645 polyester resin Substances 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
230000000379 polymerizing effect Effects 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
239000004810 polytetrafluoroethylene Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000031915 positive regulation of coagulation Effects 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
150000003138 primary alcohols Chemical class 0.000 description 1
238000002810 primary assay Methods 0.000 description 1
230000009862 primary prevention Effects 0.000 description 1
235000014059 processed cheese Nutrition 0.000 description 1
230000002947 procoagulating effect Effects 0.000 description 1
208000029397 protein Z deficiency Diseases 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
201000007183 prothrombin deficiency Diseases 0.000 description 1
235000011962 puddings Nutrition 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
238000005086 pumping Methods 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
229910052761 rare earth metal Inorganic materials 0.000 description 1
238000012892 rational function Methods 0.000 description 1
239000000376 reactant Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000004064 recycling Methods 0.000 description 1
238000007430 reference method Methods 0.000 description 1
238000000679 relaxometry Methods 0.000 description 1
230000010410 reperfusion Effects 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229960002917 reteplase Drugs 0.000 description 1
108010051412 reteplase Proteins 0.000 description 1
229960005496 reviparin Drugs 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
230000001359 rheumatologic effect Effects 0.000 description 1
VUOPFFVAZTUEGW-FBMDODLCSA-N ristocetin Chemical compound C=1C([C@@H]2C(=O)N[C@@H]([C@@H](C3=CC=C(C=C3)OC=3C=C4C=C(C=3O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](COC5[C@@H]([C@H](O)[C@@H](O)[C@H](C)O5)O)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](CO)O3)O[C@H]3[C@H]([C@H](O)[C@H](O)CO3)O)OC3=CC=C(C=C3)[C@@H](O)[C@@H]3C(=O)N[C@@H](C=5C=C(C(=C(O)C=5)C)OC=5C(O)=CC=C(C=5)[C@@H](N)C(=O)N3)C(=O)N[C@H]4C(=O)N2)O[C@H]2O[C@@H](C)[C@H](O)[C@H](N)C2)C(=O)N[C@@H](C2=CC(O)=C3)C(=O)OC)=CC=C(O)C=1C2=C3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O VUOPFFVAZTUEGW-FBMDODLCSA-N 0.000 description 1
235000012045 salad Nutrition 0.000 description 1
229960002055 saruplase Drugs 0.000 description 1
108010073863 saruplase Proteins 0.000 description 1
238000007790 scraping Methods 0.000 description 1
230000009863 secondary prevention Effects 0.000 description 1
230000000276 sedentary effect Effects 0.000 description 1
239000013049 sediment Substances 0.000 description 1
239000003001 serine protease inhibitor Substances 0.000 description 1
239000002453 shampoo Substances 0.000 description 1
229920002545 silicone oil Polymers 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
239000002356 single layer Substances 0.000 description 1
239000010802 sludge Substances 0.000 description 1
239000002002 slurry Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
235000014347 soups Nutrition 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000000264 spin echo pulse sequence Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
208000037804 stenosis Diseases 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
201000009032 substance abuse Diseases 0.000 description 1
229960003491 sulodexide Drugs 0.000 description 1
235000019465 surimi Nutrition 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
229920003051 synthetic elastomer Polymers 0.000 description 1
239000005061 synthetic rubber Substances 0.000 description 1
239000011269 tar Substances 0.000 description 1
229960000216 tenecteplase Drugs 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
238000000427 thin-film deposition Methods 0.000 description 1
108010063955 thrombin receptor peptide (42-47) Proteins 0.000 description 1
230000002537 thrombolytic effect Effects 0.000 description 1
229960005001 ticlopidine Drugs 0.000 description 1
PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
229960005062 tinzaparin Drugs 0.000 description 1
229960001060 tioclomarol Drugs 0.000 description 1
WRGOVNKNTPWHLZ-UHFFFAOYSA-N tioclomarol Chemical compound C=1C=C(Cl)C=CC=1C(O)CC(C=1C(OC2=CC=CC=C2C=1O)=O)C1=CC=C(Cl)S1 WRGOVNKNTPWHLZ-UHFFFAOYSA-N 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
230000007838 tissue remodeling Effects 0.000 description 1
DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 1
239000000606 toothpaste Substances 0.000 description 1
229940034610 toothpaste Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
102000003601 transglutaminase Human genes 0.000 description 1
238000002834 transmittance Methods 0.000 description 1
229960005032 treprostinil Drugs 0.000 description 1
PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 description 1
ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
229960002268 triflusal Drugs 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
229920006337 unsaturated polyester resin Polymers 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
229910052720 vanadium Inorganic materials 0.000 description 1
GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
208000004043 venous thromboembolism Diseases 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
235000019163 vitamin B12 Nutrition 0.000 description 1
239000011715 vitamin B12 Substances 0.000 description 1
208000002670 vitamin B12 deficiency Diseases 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1
229940019333 vitamin k antagonists Drugs 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000002351 wastewater Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1
ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical compound C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 description 1
229960001522 ximelagatran Drugs 0.000 description 1
NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1